Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?

被引:11
|
作者
Satta, Nathalie [1 ,2 ]
Frias, Miguel A. [1 ,2 ]
Vuilleumier, Nicolas [1 ,2 ]
Pagano, Sabrina [1 ,2 ]
机构
[1] Geneva Univ Hosp, Dept Diagnost, Div Lab Med, 4 Rue Gabrielle Perret Gentil, CH-1205 Geneva, Switzerland
[2] Univ Geneva, Fac Med, Dept Med Specialties, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland
基金
瑞士国家科学基金会;
关键词
HDL; atherosclerosis; autoantibodies; cardiovascular diseases; biomarker; auto-antigens; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CHOLESTEROL EFFLUX CAPACITY; CORONARY-HEART-DISEASE; ATP-BINDING CASSETTE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ELEVATED OXIDATIVE STRESS; SCAVENGER RECEPTOR BI; RHEUMATOID-ARTHRITIS; A-1; AUTOANTIBODIES;
D O I
10.2174/1381612825666190830164917
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Autoimmune diseases are closely associated with cardiovascular diseases (CVD). Over the last decades, the comprehension of atherosclerosis, the principal initiator of CVD, evolved from a lipid-centered disease to a predominant inflammatory and immune response-driven disease displaying features of auto-immunity against a broad range of auto-antigens, including lipoproteins. Among them, high density lipoproteins (HDL) are important actors of cholesterol transport and bear several anti-atherogenic properties, raising a growing interest as therapeutic targets to decrease atherosclerosis and CVD burden, with nevertheless rather disappointing results so far. Reflecting HDL composition complexity, autoimmune responses and autoantibodies against various HDL components have been reported. Results: In this review, we addressed the important complexity of humoral autoimmunity towards HDL and particularly how this autoimmune response could help improving our understanding of HDL biological implication in atherosclerosis and CVD. We also discussed several issues related to specific HDL autoantibody subclasses characteristics, including etiology, prognosis and pathological mechanisms according to Rose criteria. Conclusion: Finally, we addressed the possible clinical value of using these antibodies not only as potential biomarkers of atherogenesis and CVD, but also as a factor potentially mitigating the benefit of HDL-raising therapies.
引用
收藏
页码:3128 / 3146
页数:19
相关论文
共 50 条